228 related articles for article (PubMed ID: 22355641)
1. Polymeric human Fc-fusion proteins with modified effector functions.
Mekhaiel DN; Czajkowsky DM; Andersen JT; Shi J; El-Faham M; Doenhoff M; McIntosh RS; Sandlie I; He J; Hu J; Shao Z; Pleass RJ
Sci Rep; 2011; 1():124. PubMed ID: 22355641
[TBL] [Abstract][Full Text] [Related]
2. Fc-engineered antibodies with immune effector functions completely abolished.
Wilkinson I; Anderson S; Fry J; Julien LA; Neville D; Qureshi O; Watts G; Hale G
PLoS One; 2021; 16(12):e0260954. PubMed ID: 34932587
[TBL] [Abstract][Full Text] [Related]
3. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
4. Engineering the fragment crystallizable (Fc) region of human IgG1 multimers and monomers to fine-tune interactions with sialic acid-dependent receptors.
Blundell PA; Le NPL; Allen J; Watanabe Y; Pleass RJ
J Biol Chem; 2017 Aug; 292(31):12994-13007. PubMed ID: 28620050
[TBL] [Abstract][Full Text] [Related]
5. Fc-Fusion Drugs Have FcγR/C1q Binding and Signaling Properties That May Affect Their Immunogenicity.
Lagassé HAD; Hengel H; Golding B; Sauna ZE
AAPS J; 2019 May; 21(4):62. PubMed ID: 31062128
[TBL] [Abstract][Full Text] [Related]
6. Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases.
Ying T; Feng Y; Wang Y; Chen W; Dimitrov DS
MAbs; 2014; 6(5):1201-10. PubMed ID: 25517305
[TBL] [Abstract][Full Text] [Related]
7. Binding of divalent H-2Kd/IgG2aFc fusion protein to murine macrophage via Fc-FcR interaction.
Xiao W; Chen X; Lin Zhou ; Lu S; Liang Z; Wu X
Cell Mol Immunol; 2007 Apr; 4(2):147-51. PubMed ID: 17571461
[TBL] [Abstract][Full Text] [Related]
8. Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics.
Dumont JA; Low SC; Peters RT; Bitonti AJ
BioDrugs; 2006; 20(3):151-60. PubMed ID: 16724863
[TBL] [Abstract][Full Text] [Related]
9. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
10. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
11. Monovalent IgG4 molecules: immunoglobulin Fc mutations that result in a monomeric structure.
Wilkinson IC; Fowler SB; Machiesky L; Miller K; Hayes DB; Adib M; Her C; Borrok MJ; Tsui P; Burrell M; Corkill DJ; Witt S; Lowe DC; Webster CI
MAbs; 2013; 5(3):406-17. PubMed ID: 23567207
[TBL] [Abstract][Full Text] [Related]
12. Modified recombinant human IgG1-Fc is superior to natural intravenous immunoglobulin at inhibiting immune-mediated demyelination.
Baksmeier C; Blundell P; Steckel J; Schultz V; Gu Q; Da Silva Filipe A; Kohl A; Linnington C; Lu D; Dell A; Haslam S; Wang J; Czajkowsky D; Goebels N; Pleass RJ
Immunology; 2021 Sep; 164(1):90-105. PubMed ID: 33880776
[TBL] [Abstract][Full Text] [Related]
13. Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model.
Patel DA; Puig-Canto A; Challa DK; Perez Montoyo H; Ober RJ; Ward ES
J Immunol; 2011 Jul; 187(2):1015-22. PubMed ID: 21690327
[TBL] [Abstract][Full Text] [Related]
14. Immunity against a therapeutic xenoprotein/Fc construct delivered by gene transfer is reduced through binding to the inhibitory receptor FcγRIIb.
Liang Y; Qiu H; Glinka Y; Lazarus AH; Ni H; Prud'homme GJ; Wang Q
J Gene Med; 2011 Sep; 13(9):470-7. PubMed ID: 21786368
[TBL] [Abstract][Full Text] [Related]
15. Quantitative methods for developing Fc mutants with extended half-lives.
Kamei DT; Lao BJ; Ricci MS; Deshpande R; Xu H; Tidor B; Lauffenburger DA
Biotechnol Bioeng; 2005 Dec; 92(6):748-60. PubMed ID: 16136591
[TBL] [Abstract][Full Text] [Related]
16. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
Front Immunol; 2018; 9():932. PubMed ID: 29765376
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway.
Bitonti AJ; Dumont JA; Low SC; Peters RT; Kropp KE; Palombella VJ; Stattel JM; Lu Y; Tan CA; Song JJ; Garcia AM; Simister NE; Spiekermann GM; Lencer WI; Blumberg RS
Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9763-8. PubMed ID: 15210944
[TBL] [Abstract][Full Text] [Related]
18. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.
Davis JH; Aperlo C; Li Y; Kurosawa E; Lan Y; Lo KM; Huston JS
Protein Eng Des Sel; 2010 Apr; 23(4):195-202. PubMed ID: 20299542
[TBL] [Abstract][Full Text] [Related]
19. Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells.
Goebl NA; Babbey CM; Datta-Mannan A; Witcher DR; Wroblewski VJ; Dunn KW
Mol Biol Cell; 2008 Dec; 19(12):5490-505. PubMed ID: 18843053
[TBL] [Abstract][Full Text] [Related]
20. Engineering of Fc Multimers as a Protein Therapy for Autoimmune Disease.
Fitzpatrick EA; Wang J; Strome SE
Front Immunol; 2020; 11():496. PubMed ID: 32269572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
